Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659373 · ClinicalTrials.gov registry record · Phase 3
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
A Phase 3 study, sponsored by ETOP IBCSG Partners Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
NCT00659373 is a Phase 3 study that has completed, run by ETOP IBCSG Partners Foundation. The registered enrollment target is 86 participants.
The verdict
NCT00659373, a Phase 3 study, has completed, sponsored by ETOP IBCSG Partners Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
Study Summary
RATIONALE: Learning about the long-term effects of adjuvant tamoxifen (T), adjuvant tamoxifen with ovarian function suppression (T+OFS), and exemestane with ovarian function suppression (E+ OFS) on brain function may help doctors plan cancer treatment. PURPOSE: This study is looking at brain function in premenopausal women who are receiving adjuvant tamoxifen (T) alone against those receive adjuvant tamoxifen (T+OFS) or exemestane (E+OFS) with ovarian function suppression (OFS) for early-stage breast cancer on clinical trial IBCSG-2402.
Interventions
- DRUG Tamoxifen
- DRUG Exemestane
- DRUG triptorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2007-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659373
The ClinicalTrials.gov registry entry for NCT00659373 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ETOP IBCSG Partners Foundation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tamoxifen is the first listed.
NCT00659373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659373 about?
NCT00659373 is a clinical study titled "Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02". RATIONALE: Learning about the long-term effects of adjuvant tamoxifen (T), adjuvant tamoxifen with ovarian function suppression (T+OFS), and exemestane with ovarian function suppression (E+ OFS) on brain function may help doctors plan cancer treatment. PURPOSE: This study is looking at brain functi...
What is the current status of trial NCT00659373?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2007-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT00659373?
The interventions under investigation include: Tamoxifen (DRUG), Exemestane (DRUG), triptorelin (DRUG).
Who is sponsoring clinical trial NCT00659373?
This trial is sponsored by ETOP IBCSG Partners Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.